New drug targets tough cancers with KRAS G12V mutation
NCT ID NCT06715124
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called QTX3544, alone or with another drug (cetuximab), in people with advanced solid tumors that have a specific genetic change (KRAS G12V). The main goals are to check safety and find the right dose. About 237 adults with tumors that have not responded to prior treatment will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke Cancer Center
Durham, North Carolina, 27705, United States
-
Florida Cancer Specialists & Research Institute
Sarasota, Florida, 34232, United States
-
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, 84112, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics Mountain Region, LLC
West Valley City, Utah, 84119, United States
-
South Texas Accelerated Research Therapeutics, LLC Midwest
Grand Rapids, Michigan, 49546, United States
-
South Texas Accelerated Research Therapeutics, LLC San Antonio
San Antonio, Texas, 78229, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Yale Cancer Center
New Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.